Margaret L. Healey
YOU?
Author Swipe
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The most common CH mutations occur in the DNMT3A and TET2 genes and result in in…
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S4 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S4 shows the baseline characteristics between all CANTOS patients and the genomic subgroup patients.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S3 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S3 shows the baseline characteristics of patients by CH mutations and treatment.
View article: Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S2 shows cumulative incidence of lung cancer by treatment in patients without CH mutations, stratified by the canakinumab dose.
View article: Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S1 shows the incidence of malignancy by treatment in CANTOS.
View article: Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Table S2 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Table S2 shows the summary of CH mutation status.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Supplementary Figure S1 from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Supplementary Figure S1 shows cumulative incidence of at least one malignancy by treatment, stratified by the canakinumab dose.
View article: Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Data from Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial Open
Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The most common CH mutations occur in the DNMT3A and TET2 genes and result in in…
View article: Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy Open
Background Prognostic markers and biological pathways linked to detrimental clinical outcomes in heart failure with preserved ejection fraction (HFpEF) remain incompletely defined. Methods and Results We measured serum levels of 4123 uniqu…
View article: Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial
Effects of IL-1β inhibition on anemia and clonal hematopoiesis in the randomized CANTOS trial Open
Canakinumab, a monoclonal antibody targeting proinflammatory cytokine interleukin-1β (IL-1β), improved hemoglobin levels while preventing recurrent cardiovascular events in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTO…
View article: P1339: IMPACT OF CLONAL HEMATOPOIESIS AND CANAKINUMAB ON NON-HEMATOLOGICAL MALIGNANCY: ANALYSIS OF THE CANTOS RANDOMIZED CLINICAL TRIAL
P1339: IMPACT OF CLONAL HEMATOPOIESIS AND CANAKINUMAB ON NON-HEMATOLOGICAL MALIGNANCY: ANALYSIS OF THE CANTOS RANDOMIZED CLINICAL TRIAL Open
Topic: 23. Hematopoiesis, stem cells and microenvironment Background: Canakinumab is a fully human monoclonal antibody that neutralizes interleukin (IL)-1β. In the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) – a random…
View article: Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy‐associated genes: A subgroup analysis of the PARADIGM‐HF trial
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy‐associated genes: A subgroup analysis of the PARADIGM‐HF trial Open
Aims To evaluate the prevalence of pathogenic variants in genes associated with dilated cardiomyopathy (DCM) in a clinical trial population with heart failure and reduced ejection fraction (HFrEF) and describe the baseline characteristics …